Literature DB >> 17033848

Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters.

Marinke Westerterp1, Jan Pruim, Wim Oyen, Otto Hoekstra, Anne Paans, Eric Visser, Jan van Lanschot, Gerrit Sloof, Ronald Boellaard.   

Abstract

PURPOSE: Standardised uptake values (SUVs) depend on acquisition, reconstruction and region of interest (ROI) parameters. SUV quantification in multi-centre trials therefore requires standardisation of acquisition and analysis protocols. However, standardisation is difficult owing to the use of different scanners, image reconstruction and data analysis software. In this study we evaluated whether SUVs, obtained at three different institutes, may be directly compared after calibration and correction for inter-institute differences.
METHODS: First, an anthropomorphic thorax phantom containing variously sized spheres and activities, simulating tumours, was scanned and processed in each institute to evaluate differences in scanner calibration. Secondly, effects of image reconstruction and ROI method on recovery coefficients were studied. Next, SUVs were derived for tumours in 23 subjects. Of these 23 patients, four and ten were scanned in two institutes on an HR+ PET scanner and nine were scanned in one institute on an ECAT EXACT PET scanner. All phantom and clinical data were reconstructed using iterative reconstruction with various iterations, with both measured (MAC) and segmented attenuation correction (SAC) and at various image resolutions. Activity concentrations (AC) or SUVs were derived using various ROI isocontours.
RESULTS: Phantom data revealed differences in SUV quantification of up to 30%. After application-specific calibration, recovery coefficients obtained in each institute were equal to within 15%. Varying the ROI isocontour value resulted in a predictable change in SUV (or AC) for both phantom and clinical data. Variation of image resolution resulted in a predictable change in SUV quantification for large spheres/tumours (>5 cc) only. For smaller tumours (<2 cc), differences of up to 40% were found between high (7 mm) and low (10 mm) resolution images. Similar differences occurred when data were reconstructed with a small number of iterations. Finally, no significant differences between MAC and SAC reconstructed data were observed, except for tumours near the diaphragm.
CONCLUSION: Standardisation of acquisition, reconstruction and ROI methods is preferred for SUV quantification in multi-centre trials. Small unavoidable differences in methodology can be accommodated by performing a phantom study to assess inter-institute correction factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033848     DOI: 10.1007/s00259-006-0224-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  25 in total

1.  Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling.

Authors:  R Boellaard; A van Lingen; A A Lammertsma
Journal:  J Nucl Med       Date:  2001-05       Impact factor: 10.057

2.  Evaluating image reconstruction methods for tumor detection in 3-dimensional whole-body PET oncology imaging.

Authors:  Carole Lartizien; Paul E Kinahan; Richard Swensson; Claude Comtat; Michael Lin; Victor Villemagne; Régine Trébossen
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

3.  Performance evaluation of the positron scanner ECAT EXACT.

Authors:  K Wienhard; L Eriksson; S Grootoonk; M Casey; U Pietrzyk; W D Heiss
Journal:  J Comput Assist Tomogr       Date:  1992 Sep-Oct       Impact factor: 1.826

Review 4.  Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.

Authors:  Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

5.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

7.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

Review 8.  Monitoring response to treatment in patients utilizing PET.

Authors:  Norbert E Avril; Wolfgang A Weber
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

9.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

10.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

View more
  86 in total

1.  Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database.

Authors:  John Caddell Dickson; Livia Tossici-Bolt; Terez Sera; Robin de Nijs; Jan Booij; Maria Claudia Bagnara; Anita Seese; Pierre Malick Koulibaly; Umit Ozgur Akdemir; Cathrine Jonsson; Michel Koole; Maria Raith; Markus Nowak Lonsdale; Jean George; Felicia Zito; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01       Impact factor: 9.236

2.  Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer.

Authors:  Kazuhiro Kitajima; Masato Kita; Kayo Suzuki; Michio Senda; Yuji Nakamoto; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-17       Impact factor: 9.236

3.  Variability in PET quantitation within a multicenter consortium.

Authors:  Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint
Journal:  Med Phys       Date:  2010-07       Impact factor: 4.071

4.  Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.

Authors:  R K Doot; J S Scheuermann; P E Christian; J S Karp; P E Kinahan
Journal:  Med Phys       Date:  2010-11       Impact factor: 4.071

5.  Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study.

Authors:  Takayuki Kadoya; Kenjiro Aogi; Sachiko Kiyoto; Norio Masumoto; Yoshifumi Sugawara; Morihito Okada
Journal:  Breast Cancer Res Treat       Date:  2013-09-13       Impact factor: 4.872

6.  The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions.

Authors:  Masatoyo Nakajo; Seishi Jinnouchi; Yoshihiko Fukukura; Hiroaki Tanabe; Rie Tateno; Masayuki Nakajo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

7.  Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer.

Authors:  Hyun Hoon Chung; Gi Jeong Cheon; Hee Seung Kim; Jae Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

8.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

Review 9.  The role of functional imaging in the era of targeted therapy of renal cell carcinoma.

Authors:  Margarita Braunagel; Anno Graser; Maximilian Reiser; Mike Notohamiprodjo
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

10.  Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Authors:  L Tessonnier; F Sebag; F F Palazzo; C Colavolpe; C De Micco; J Mancini; B Conte-Devolx; J F Henry; O Mundler; D Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.